Rubius Therapeutics (NASDAQ: RUBY) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Rubius Therapeutics to related businesses based on the strength of its institutional ownership, risk, profitability, dividends, earnings, analyst recommendations and valuation.
Valuation & Earnings
This table compares Rubius Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Rubius Therapeutics||N/A||-$89.19 million||-7.28|
|Rubius Therapeutics Competitors||$897.64 million||$190.37 million||-1.39|
This table compares Rubius Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Rubius Therapeutics Competitors||-5,144.22%||-64.24%||-27.96%|
Institutional and Insider Ownership
87.1% of Rubius Therapeutics shares are owned by institutional investors. Comparatively, 48.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 58.4% of Rubius Therapeutics shares are owned by insiders. Comparatively, 16.4% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a breakdown of current ratings and price targets for Rubius Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Rubius Therapeutics Competitors||842||2786||6090||262||2.58|
Rubius Therapeutics presently has a consensus target price of $37.00, suggesting a potential upside of 123.84%. As a group, “Biological products, except diagnostic” companies have a potential upside of 38.11%. Given Rubius Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Rubius Therapeutics is more favorable than its rivals.
Rubius Therapeutics beats its rivals on 8 of the 12 factors compared.
Rubius Therapeutics Company Profile
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.